New 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidine (PMEO-DAPy) and 1-[2-(phosphonomethoxy)ethyl]-5-azacytosine (PME-5-azaC) prodrugs were prepared with a pro-moiety consisting of carbonyloxymethyl esters (POM, POC), alkoxyalkyl esters, amino acid phosphoramidates and/or tyrosine. The activity of the prodrugs was evaluated in vitro against different virus families. None of the synthesized prodrugs demonstrated activity against RNA viruses but some of them proved active against herpesviruses [including herpes simplex virus (HSV), varicella-zoster virus (VZV), and human cytomegalovirus (HCMV)]. The bis(POC) and the bis(amino acid) phosphoramidate prodrugs of PMEO-DAPy inhibited herpesvirus replication at lower doses than the parent compound although the selectivity against HSV and VZV was only slightly improved compared to PMEO-DAPy. The mono-octadecyl ester of PME-5-azaC emerged as the most potent and selective PME-5-azaC prodrug against HSV, VZV and HCMV with EC 50 's of 0.15-1.12 mM while PME-5-azaC only had marginal anti-herpesvirus activity. Although the bis (hexadecylamido-L-tyrosyl) and the bis(POM) esters of PME-5-azaC were also very potent anti-herpesvirus drugs, these were less selective than the mono-octadecyl ester prodrug.
Introduction
Acyclic nucleoside phosphonates (ANPs) are compounds of great importance due to the broad spectrum of biological activities, especially antiviral but also cytostatic, immunomodulatory and antiparasitic. [1] [2] [3] [4] Some of them have become already clinically available drugs: cidofovir for the treatment of human cytomegalovirus (CMV) retinitis in AIDS patients, adefovir in a prodrug form as adefovir dipivoxil for the treatment of hepatitis B (HBV) and tenofovir, either as tenofovir disoproxil fumarate, or newly (since 2015) also as a new prodrug form tenofovir alafenamide (TAF) for the treatment of HIV and HBV infections. On the other hand, it should be noted that over the last thirty years of systematic investigation of ANPs, there are dozens of other therapeutically attractive structures synthesized but never advanced to the stage of preclinical/clinical investigations. 5 These structures are namely a) antiretroviral purine 3-fluoro-2-[(phosphonomethoxy)propyl] derivatives, 6 b) acyclic nucleoside phosphonates with 5-azacytosine base moiety, [8] [9] [10] and d) aza/deaza analogues of purine [(phosphonomethoxy)ethyl] derivatives. 11 The common structural attribute of all ANPs is their highly polar character caused by the presence of the phosphonic acid residue which is responsible for their unfavourable pharmacological properties: low cell permeability and low oral bioavailability. To overcome this problem, transformation of free acyclic nucleoside phosphonates to appropriate prodrugs is often a solution.
In our work, we focus on two pharmacologically interesting ANP structures: 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidine -an example of the so-called ''open-ring" ANPs and on the group of 5-azacytosine derivatives, namely 1-[2-(phosphonomethoxy)ethyl]-5-azacytosine, and their antiviral potential in diverse prodrug forms.
Open-ring ANPs are characterized by the phosphonomethoxy group containing an aliphatic part linked to the position 6 of 2,4-diaminopyrimidine via the oxygen atom. They are evidently mimics of the appropriate 2,6-diaminopurine derivatives with an open imidazole ring. Their antiviral activity is essentially identical to that of their parent compounds, including the enantiomeric specificity. Compounds as PMEO-DAPy, (R)-PMPO-DAPy and 5-substituted PMEO-DAPy ( Fig. 1 ) are very efficient inhibitors of the new compounds fulfilled this criterion, we managed to find a new class of antiviral agents, 5-azacytosine analogue of cidofovir 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine (HPMP-5-azaC) and various ester prodrugs derived from its cyclic form (Fig. 2) . 7, 14 Compared to cidofovir, HPMP-5-azaC has improved selectivity. The prodrug hexadecyloxyethyl ester of its cyclic form (HDE-cHPMP-5-azaC) revealed the most potent anti-DNA virus activities and also the highest selectivity indices (ratio activity vs toxicity) in the order of thousands, e.g. 1160 for herpes simplex virus (HSV) ! 5800 for varicella zoster virus (VZV) and !24,600 for HCMV. 14 The only disadvantage of HPMP-5-azaC is its complicated metabolic profile bound to instability of the 5-azacytosine ring in alkaline conditions including physiological pH. Studying the stability of various 5-azacytosine ANPs, we found much better stability for another 5-azacytosine derivative, i.e. 1-[2-(phosphonomethoxy)ethyl]-5-azacytosine (PME-5-azaC). 15 Despite the fact that its antiviral activity was only marginal in the free phosphonic acid form 7 , we selected the compound for syntheses and further studies of its prodrug forms. We considered the fact that the activities of many ANPs were increased after transformation to appropriate prodrugs. Moreover, in some cases not only the activity was enhanced but also the spectrum of activity could be broaden by transformation to prodrugs. Typical examples are the anti-DNA viral agents 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine (HPMPA) whose octadecyloxyethyl (ODE) ester is a potent and selective inhibitor of hepatitis C virus replication 16 or cidofovir transformed to its hexadecyloxyethyl ester (brincidofovir) whose efficacy is also enlarged to some RNA viral infections including Ebola virus. In fact, the lipid moiety of brincidofovir was found to be required for in vitro antiviral activity against Ebola virus. 
Chemistry
The starting compound 2,4-diamino-6-[2-(phosphonomethoxy) ethoxy]pyrimidine (1) was synthesized according to a procedure described in the literature. 8 Briefly: base-catalysed alkylation of 2,4-diamino-6-hydroxypyrimidine with diisopropyl 2-(chloroethoxy)methylphosphonate gave a mixture of appropriate Oand N-diisopropyl (phosphonoethoxy)methyl derivatives where the N-isomer was separated and diisopropyl ester groups deprotected with bromotrimethylsilane. The synthesis of the prodrugs was rather complicated by a low solubility of the starting PMEODAPy; finally we managed to synthesize two biodegradable ester prodrugs -pivaloyloxymethyl (POM) and (isopropoxycarbonyl) oxymethyl (POC) esters and the amino acid phosphoramidate prodrug (Scheme 1). Pivaloyloxymethylation was performed by reaction of the starting phosphonic acid with chloromethyl pivalate using N,N 0 -dicyclohexyl-4-morpholinecarboxamidine as a base. The reaction proceeded very slowly to give a mixture of bis (POM) and mono(POM) esters 2 and 3. After chromatographic separation, both compounds were isolated in acceptable yields. Alternative reaction conditions (e.g. reaction in dioxane with DBU) completely failed. Also for the introduction of POC groups, different attempts have been examined (various solvents, DBU or diisopropylethylamine as bases). The only way that led to the bis (POC) derivative 4 consisted in transformation of free PMEO-DAPy to its tetrabutylammonium salt, followed by heating with POCchloride in dioxane. The bis(amino acid) phosphoramidate prodrug 5 was prepared by the direct coupling of PMEO-DAPy with ethyl Lalaninate in pyridine and treatment with a premixed solution of triphenylphosphine and 2,2 0 -dipyridyl disulfide (Aldrithiol and tyrosine based prodrugs. The introduction of POC and POM groups has been performed by the action of appropriate alkyl chloride and N,N 0 -dicyclohexyl-4-morpholinecarboxamidine in dimethylformamide, i.e. conditions described for transformation of adefovir to adefovir dipivoxil 18 (Scheme 2). Unfortunately, and contrary to adefovir, reactivity and solubility of PME-5-azaC (6) was much lower giving the appropriate diesters 7 and 9 in modest yields only, accompanied by formation of monoesters. In pivaloyloxymethylation of PME-5-azaC, the mono-POM derivative 8 was even obtained as the main reaction product. The amino acid phosphoramidates 12 and 13 were synthesized by the method developed by Jansa starting from the phosphonate dialkyl esters. 19 Diisopropyl or diethyl esters are formed as common intermediates in syntheses of all ANPs; their deprotection with bromotrimethylsilane leads to the bis(trimethylsilyl) esters in situ which are further hydrolysed to the final phosphonic acids. The principle of this method is the utilization of the intermediary bis(trimethylsilyl) ester of ANP directly for reaction with 2,2 0 dithiodipyridine, triphenylphosphine and amino acid ester to obtain bis-amidates without the need of laborious procedures to isolate the free phosphonic acids. The selection of amino acid esters is directed especially to diethyl esters of L-alanine or Lphenylalanine leading to prodrugs with optimal pharmacokinetic profile. 20 In our case, we selected the diethyl ester of L-phenylalanine (Scheme 3). Similarly as with the preparation of POM and POC esters, we obtained not only the desired symmetrical bis-amidate prodrug 12 but also mono-amidate 13 accompanied by a small amount of mono-methyl ester 14. Compound 14 was formed most probably during the chromatographic separation of the mono-amidate prodrug in a system containing high percentage of methanol. Another type of prodrugs selected for our studies include alkoxyalkylesters. 21 The concept of these prodrugs is based on the mimicking of naturally occurring phospholipid lysophosphatidylcholine (LPC). The compounds use the LPC natural uptake pathway in the small intestine to reach the target tissue and achieve oral bioavailability. The most important compound of this family is the hexadecyloxypropyl ester of cidofovir (brincidofovir, CMX-001), currently in Phase III clinical trials for use in humans against HCMV and adenovirus infections. This compound is also being investigated as an experimental drug against smallpox and ebolavirus infections. 22 In our previous studies, we have successfully applied the alkoxyalkylester approach to 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine ((S)-HPMPDAP) 23 within the search for new bioavailable anti-poxvirus agents and for the synthesis of the above mentioned HDE-cHPMP-5-azaC (Fig. 2) . 14 In our synthesis, the starting PME-azaC was transformed first to its tetrabutylammonium salt, which was subsequently treated with hexadecyloxypropyl bromide to give the mixture of diester and monoester (15, 17) . The monoester 17 is predominant most probably for steric reasons. Besides, small amounts of N 4 -alkylated product 16 were isolated (Scheme 4).
The last type of prodrugs included in this study are amino acid ester prodrugs where esterification of the phosphonic acid residue is performed via the free hydroxyl group of the appropriate hydroxy amino acid (serine, valine, tyrosine). This concept has been originally developed by McKenna's group to improve the oral bioavailability of (S)-HPMPC and (S)-HPMPA. 24, 25 Pharmacokinetic studies of various amino acid or dipeptide prodrugs of these ANPs finally revealed that the tyrosine single amino acid was the most favorable promoiety regarding prodrug plasma stability. It was also found that enzymatic stability of the tyrosine promoiety can be significantly increased by replacement of the carboxyl ester with an alkyl amide group. The highest increase in bioavailability and antiviral activity was observed when a long lipophilic alkyl chain was incorporated into the tyrosine amide group. A comprehensive review including synthesis, SAR studies and pharmacology of tyrosine N-alkyl amide ANP prodrugs has been published recently.
26
Considering these findings, we decided to synthesize the symmetrical bis-tyrosine prodrug 23 whose carboxylic function is modified by the hexadecylamido group (Scheme 5). The compound can be prepared via alkylation of the 5-azacytosine sodium salt with the whole aliphatic moiety, i.e. BOC protected bis(hexadecylamido-Ltyrosyl) ester of 2-(phosphonomethoxy)ethyl chloride (21) prepared previously and followed by acidic removal of the protecting BOC groups. The tyrosine synthon 21 can be obtained by multistep synthesis from diisopropyl 2-(phosphonomethoxy)ethyl chloride (18) which is known as a common building block in the synthesis of diverse PME derivatives. 27 Isopropyl groups in 18 were removed first by the action of bromotrimethylsilane followed by hydrolysis. The intermediary phosphonic acid 19 was then activated by reaction with oxalyl chloride in DMF forming a phosphorodichloridate 28 whose further reaction with BOC-protected hexadecyl tyrosine amide 20 in a presence of triethylamine formed diester 21 in good preparative yield. Tyrosine amide precursor 20 was prepared from N-BOC-L-tyrosine by standard coupling procedure using EDC and N-hydroxybenzotriazole (HOBt) in CH 2 Cl 2 (similarly as described for other alkylated L-tyrosine amides, e.g. octyl or octadecyl). 
Antiviral activity
All the synthesized compounds were tested for their antiviral activities against: (a) human cytomegalovirus (HCMV), varicellazoster virus (VZV) wild type and thymidine kinase deficient (TK (Table 1) . Among the synthesized PMEO-DAPy prodrugs, the bis(amino acid) phosphoramidate prodrug 5 emerged as the most active one against HSV, VZV and HCMV. The bis(POC) prodrug 4 was as active as compound 5 against HSV and VZV but proved less effective against HCMV. These prodrugs were 6-20-fold (HSV) and 3-16-fold (VZV) more active than the parental drug PMEODAPy and they gained activity against HCMV (EC 50 's of 17-29 mM and 86-90 mM for, respectively, compounds 5 and 4 versus >100 mM for compound 1). Together with an increase in antiviral potency, an augmentation of the CC 50 (50% cytostatic concentration) was seen for compounds 4 and 5 when compared to PMEODAPy. As a consequence, when calculating the selectivity index (SI, ratio: CC 50 /EC 50 ) for the prodrugs 4 and 5 against HCMV, no selectivity was seen (SI's 1). However, these two prodrugs selectively inhibited HSV and VZV replication with SI's of, respectively, 4-15 and 15-52, which was slightly better than the SI's for PMEO-DAPy, i.e. 1.7-4.5 (HSV) and 19-44 (VZV).
Pivaloyloxymethylation of PMEO-DAPy led to the synthesis of the bis(POM) and mono(POM) esters 2 and 3 but this strategy did not result in improvement of the anti-herpesvirus activity. Thus, the mono(POM) 3 prodrug had a potency and selectivity virtually identical to PMEO-DAPy while the bis(POM) 2 prodrug was 2 to 4.5-fold more active than PMEO-DAPy but 5.5-fold more cytostatic which resulted in decreased selectivity compared to the parental drug.
Among the carbonyloxymethyl esters (POM, POC) based prodrugs of PME-5-azaC, the bis(POM) compound 9 exhibited improved activity compared to the parent PME-5-azaC which had marginally activity against herpesviruses. The bis(POM) prodrug 9 inhibited the replication of HSV, VZV and HCMV with EC 50 0 s in the range of, respectively, 0.7-1.3 mM, 0.7-1.3 mM and 1-3 mM and had substantial selectivity [i.e. SI's of 37-63 (HSV), 35-71 (VZV) and 14-47 (HCMV)]. In contrast to the bis(POM) prodrug 9, the mono(POM) prodrug 8 and its sodium salt (i.e. compound 10), presented minimal or no anti-herpesvirus activities. The bis (POC) prodrug 7 demonstrated some anti-herpesvirus activity (EC 50 values in the range of 15-22 mM) but was markedly less potent than the bis(POM) prodrug 9. Regarding the synthesized amino acid phosphoramidates prodrugs, the mono-amidate 13 and the mono-methyl ester 14 lacked activity against herpesviruses while the bis-amidate prodrug 12 inhibited herpesvirus replication with EC 50 's of 32-42 mM (HSV), 27-29 mM (VZV) and 7.5-15.5 mM (HCMV). Notably, compound 12 was not toxic for cell growth and cell morphology up to the highest concentration tested (i.e. 100 mM).
Amongst the alkoxyalkyl esters, the bis(octadecyloxytheyl) ester 15 and the N 4 -alkylated prodrug 16 were deprived of antiherpesvirus properties while the mono-octadecyloxyethyl ester 17 emerged as one of the most active prodrugs with EC 50 's of Table 1 Antiviral and cytotoxic properties of the synthesized compounds in human embryonic lung (HEL) cells. Compound 
The bis(POM) ester 9 was the only PME-5-azaC prodrug showing weak activity against vaccinia virus (EC 50 = 152 mM) although no selectivity was observed (Table 1) 
Conclusions
We have successfully synthesized carbonyloxymethyl esters (POM, POC), alkoxyalkyl esters, amino acid phosphoramidates and tyrosine based prodrugs of PMEO-DAPy and/or PME-5-azaC that had weak or marginal activity against herpesviruses. The mono-octadecyloxyethyl ester of PME-5-azaC emerged as the most potent and selective inhibitor of herpesviruses (i.e. HSV, VZV and HCMV). The bis(hexadecylamido-L-tyrosyl) and the bis(POM) esters of PME-5-azaC also had potent anti-herpesvirus activity but less selectivity that the mono-octadecyloxyethyl prodrug. The bis(POC) and bis(amino acid) phosphoramidate prodrugs of PMEO-DAPy proved more active than the parental drug against HSV, VZV and HCMV, showing selectivity for HSV and VZV but not for HCMV.
Experimental

General
Unless stated otherwise, solvents were evaporated at 40°C/2 kPa and compounds were dried at 13 Pa. Analytical TLC was performed on silica gel 60 F 254 plates (Merck KGaA, Darmstadt, Germany); chromatographic systems are described in text. Column chromatography was performed on silica gel 60 lm (Fluka). 1 H, 13 C and 31 P NMR spectra were measured on Bruker AVANCE III 500 and/ or 600 spectrometers equipped with a cryoprobe and operating at 500.0 or 600. and its decomposition by-products), followed by system ethyl acetate-acetone-ethanol-water (15:3:4:3) to give bis(POM) derivative 2. Further elution of the column with methanol afforded mono-POM prodrug 3. 
Bis[(isopropoxycarbonyl)oxymethyl] ester of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidine (4)
1 M methanolic solution of tetrabutylammonium hydroxide (1 mL) was added to a suspension of 1 (264 mg, 1 mmol) in absolute MeOH (75 mL) and the suspension stirred vigorously or treated in ultrasonic bath to dissolution. The clear solution was evaporated and the residue coevaporated with dioxane (2 Â 25 mL). Dry dioxane (25 mL) was added, followed by POC chloride (2.6 mL, 20 mmol) and the mixture heated to 85°C for 4 h. Reaction course was monitored by TLC in 15% methanol in chloroform. The mixture was set aside at room temperature overnight and evaporated. The residue was partitioned between water and chloroform (50 mL each), the organic layer dried over Na 2 SO 4 and evaporated. The residue was chromatographed on silica gel in a gradient 5-15% methanol in chloroform. Yield 100 mg (20%) of a white amorphous solid. 
Bis(L-alanine ethyl ester) prodrug of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidine (5)
A solution consisting of 1 (730 mg, 2.76 mmol), ethyl L-alaninate (1.7 g, 11 mmol), triethylamine (6 mL) and pyridine (25 mL) was heated to 60°C for 5 min (solution A). Triphenylphosphine (4.3 g, 16 mmol) and Aldrithiol (3.5 g, 16 mmol) were dissolved in pyridine (16 mmol) and this solution added to the solution A. The whole reaction mixture was heated to 60°C for 4 h, set aside at room temperature overnight and evaporated. The residue was coevaporated with toluene and chromatographed on a column of silica gel (700 mL), starting with system 5% methanol in chloroform (elution of triphenylphosphine oxide and mercaptopyridine), followed by the gradient 5-50% methanol in chloroform. The crude sirupy product 5 (1.25 g) still containing rests of ethyl L-alaninate was purified by further chromatography on silica gel in system ethyl acetateacetone-ethanol-water (18: 
Reaction of 1-[2-(phosphonomethoxy)ethyl]-5-azacytosine (6) with (isopropoxycarbonyl)oxymethyl chloride
A mixture of 6 (500 mg, 2 mmol), N,N-dicyclohexyl-4-morpholinecarboxamidine (1.16 g, 4 mmol) and POC-Cl (0.8 mL, 6 mmol) in DMF (30 mL) was stirred at room temperature for 3 days. The mixture was evaporated, the residue coevaporated with toluene (2 Â 50 mL) and chromatographed on a silica gel column starting with ethyl acetate (elution of the rest of POC-Cl), followed by system ethyl acetate-acetone-ethanol-water (15:3:4:3) to give diester 7 (R F 0.70) and monoester 8 (R F 0.20).
Bis[(isopropoxycarbonyl)oxymethyl] ester of 1-[2-(phosphonomethoxy)ethyl]-5-azacytosine (7)
Yield 85 mg (9%) of a white solid. 
Pivaloyloxymethylation of 1-[2-(phosphonomethoxy)ethyl]-5-azacytosine
Reaction of PME-5-azaC 6 (450 mg, 1.8 mmol) with POMÀCl (0.9 mL, 6.5 mmol) was performed under the same conditions as described previously for 7 and 8. Chromatography in system ethyl acetate-acetone-ethanol-water (15:3:4:3) afforded bis(POM) ester 9 (R F 0.75) and mono(POM) ester 10 (R F 0.25). 501.17187.
Pivaloyloxymethyl ester of 1-[2-(phosphonomethoxy)ethyl]-5-azacytosine, sodium salt (10)
The crude product (620 mg, still in the form of dicyclohexylmorpholinocarboxamidine salt) was applied onto a column of Dowex 50 (Na + form, 50 mL) and eluted with water. UV absorbing fraction was evaporated to give sodium salt of 10 in yield 150 mg (22%) as a white solid. 
Synthesis of amidate prodrugs of 1-[2-(phosphonomethoxy) ethyl]-5-azacytosine
Diisopropyl ester 11 (1.1 g, 3.29 mmol) in acetonitrile (30 mL) was stirred with bromotrimethylsilane (2.2 mL, 16.5 mmol) at room temperature for 24 h. The mixture was evaporated and the residue coevaporated with toluene (2 Â 50 mL). A mixture consisting of: diethyl (L)-phenylalanine hydrochloride (3.0 g, 13.1 mmol), pyridine (26 mL) and triethylamine (6.5 mL) was added under argon. The resulting mixture was heated to 60°C for 5 min. A solution of Ph 3 P (5.2 g, 19.74 mmol) and Aldrithiol (4.35 g, 19.7 mmol) in pyridine (20 mL) was added, the reaction mixture heated to 50°C for 3 h, then set aside at room temperature overnight and evaporated. The residue was coevaporated with toluene (3 Â 40 ml), applied onto column of silica gel and subjected to flash chromatography starting with chloroform (elution of Ph 3 P). Additional elution was performed with a gradient 1-20% MeOH in chloroform (elution of Ph 3 P-O, followed by pyridine-thiol). Bis-amidate 12 was eluted subsequently, in system 20% MeOH in chloroform. Product containing fractions were evaporated and dried in vacuo. 
(L-Phenylalanine ethyl ester) prodrug of 1-[2-(phosphonomethoxy)ethyl]-5-azacytosine (13)
After elution of bis(amidate) 12, the column was eluted with methanol. The UV absorbing eluate was concentrated, adsorbed to a small amount of silica gel (20-30 mL) and applied onto a column of silica gel (broad and short column, 150 mL). Elution with system ethyl acetate-acetone-ethanol-water (15:3:4:3) afforded monoamidate prodrug 13 (R F 0.2) in yield 248 mg (18%) as a white solid.
1 H NMR (CD 3 OD, ppm) d: 1.14 (t, 3H, J CH3,CH2 = 7.2, CH 3 ), 2.92
(dd, 1H, J P,CHa = 7.0, J gem = 13.3, CH a -Ph), 2.98 (dd, 1H, J P,CHb = 6.3, a stirred suspension of 6 (1.5 g, 6 mmol) in absolute MeOH (50 mL). After 5 min, the resulting solution was evaporated and the residue coevaporated with DMF. Dry DMF (35 mL) and ODE-Br (5.6 g, 15 mmol) were added and the reaction mixture heated to 105°C for 5 h. The mixture was evaporated, the residue partitioned between chloroform and water, an organic layer dried over magnesium sulphate and evaporated. The residue was chromatographed on a column of silica gel (800 mL) in system 7.5% methanol in CHCl 3 to give crude products 16 (R F 0.48) and 15 (R F 0.28). Both compounds required further purification (see below). Further elution of the column with methanol afforded the crude monoester 17 (its further purification described below). 
[(2-Chloroethoxy)methyl]phosphonic acid (19)
A mixture of 18 (3 g, 10.6 mmol) and bromotrimethylsilane (15 mL, 119.8 mmol) in acetonitrile (65 mL) was stirred overnight at room temperature, then evaporated and coevaporated with water (2 Â 20 mL). The mixture was dissolved in water (50 mL) and extracted with diethyl ether (3 Â 10 mL). The aqueous layer was evaporated, the residue coevaporated with toluene (2 Â 20 mL) and dried under reduced pressure to dryness. Yield: 2.1 g (56.9%) of a colorless oil. 1 (21) was heated at 95°C for 16 h (dissolution occurs). The solution was evaporated, the residue coevaporated with toluene (2 Â 50 mL) and applied onto a column of silica gel (400 mL). Elution was started with ethyl acetate (elution of the rest of 21 and nonpolar by-products), followed by system ethyl acetate-acetone-ethanol-water (18:3:2:2, R F of the product 22: 0.50). Nevertheless, 22 is bound to silica gel very strongly and its elution from the column proceeds after further addition of methanol to ratio: ethyl acetateacetone-ethanol-water (18:3:2:2)/MeOH (1:1). Yield: 600 mg (21%) of a glassy amorphous solid. 
